<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Adv Ther</journal-id><journal-id journal-id-type="iso-abbrev">Adv Ther</journal-id><journal-title-group><journal-title>Advances in Therapy</journal-title></journal-title-group><issn pub-type="ppub">0741-238X</issn><issn pub-type="epub">1865-8652</issn><publisher><publisher-name>Springer Healthcare</publisher-name><publisher-loc>Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4713958</article-id><article-id pub-id-type="publisher-id">150</article-id><article-id pub-id-type="doi">10.1007/s12325-014-0150-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR<sup>+</sup> Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Yardley</surname><given-names>Denise A.</given-names></name><address><email>dyardley@tnonc.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Noguchi</surname><given-names>Shinzaburo</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Pritchard</surname><given-names>Kathleen I.</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Burris</surname><given-names>Howard A.</given-names><suffix>III</suffix></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Baselga</surname><given-names>Jos&#x000e9;</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Gnant</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Hortobagyi</surname><given-names>Gabriel N.</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Campone</surname><given-names>Mario</given-names></name><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Pistilli</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="Aff8"/></contrib><contrib contrib-type="author"><name><surname>Piccart</surname><given-names>Martine</given-names></name><xref ref-type="aff" rid="Aff9"/></contrib><contrib contrib-type="author"><name><surname>Melichar</surname><given-names>Bohuslav</given-names></name><xref ref-type="aff" rid="Aff10"/></contrib><contrib contrib-type="author"><name><surname>Petrakova</surname><given-names>Katarina</given-names></name><xref ref-type="aff" rid="Aff11"/></contrib><contrib contrib-type="author"><name><surname>Arena</surname><given-names>Francis P.</given-names></name><xref ref-type="aff" rid="Aff12"/></contrib><contrib contrib-type="author"><name><surname>Erdkamp</surname><given-names>Frans</given-names></name><xref ref-type="aff" rid="Aff13"/></contrib><contrib contrib-type="author"><name><surname>Harb</surname><given-names>Wael A.</given-names></name><xref ref-type="aff" rid="Aff14"/></contrib><contrib contrib-type="author"><name><surname>Feng</surname><given-names>Wentao</given-names></name><xref ref-type="aff" rid="Aff15"/></contrib><contrib contrib-type="author"><name><surname>Cahana</surname><given-names>Ayelet</given-names></name><xref ref-type="aff" rid="Aff15"/></contrib><contrib contrib-type="author"><name><surname>Taran</surname><given-names>Tetiana</given-names></name><xref ref-type="aff" rid="Aff15"/></contrib><contrib contrib-type="author"><name><surname>Lebwohl</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff15"/></contrib><contrib contrib-type="author"><name><surname>Rugo</surname><given-names>Hope S.</given-names></name><xref ref-type="aff" rid="Aff16"/></contrib><aff id="Aff1"><label/>Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN 37203 USA </aff><aff id="Aff2"><label/>Department of Breast and Endocrine Surgery, Osaka University, Suita, Osaka 565-0871 Japan </aff><aff id="Aff3"><label/>Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, ON M4N 3M5 Canada </aff><aff id="Aff4"><label/>Memorial Sloan-Kettering Cancer Center, New York, NY 10065 USA </aff><aff id="Aff5"><label/>Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria </aff><aff id="Aff6"><label/>The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA </aff><aff id="Aff7"><label/>Institut de Canc&#x000e9;rologie de l&#x02019;Ouest, Ren&#x000e9; Gauducheau, Centre de Recherche en Canc&#x000e9;rologie, 44805 Nantes Saint Herblain, France </aff><aff id="Aff8"><label/>Department of Medical Oncology, Ospedale di Macerata, 62100 Macerata, Italy </aff><aff id="Aff9"><label/>Institut Jules Bordet, Universit&#x000e9; Libre de Bruxelles, 1000 Brussels, Belgium </aff><aff id="Aff10"><label/>Department of Oncology, Palacky University Medical School and Teaching Hospital, 775 20 Olomouc, Czech Republic </aff><aff id="Aff11"><label/>Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic </aff><aff id="Aff12"><label/>NYU Langone Arena Oncology, P.C., Lake Success, NY 11042 USA </aff><aff id="Aff13"><label/>Department of Medical Oncology, Orbis Medical Center, 6162 BG Sittard-Geleen, The Netherlands </aff><aff id="Aff14"><label/>Horizon Oncology, Lafayette, IN 47905 USA </aff><aff id="Aff15"><label/>Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936 USA </aff><aff id="Aff16"><label/>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115 USA </aff></contrib-group><pub-date pub-type="epub"><day>11</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="ppub"><year>2014</year></pub-date><volume>31</volume><fpage>1008</fpage><lpage>1009</lpage><permissions><copyright-statement>&#x000a9; Springer Healthcare 2014</copyright-statement></permissions><related-article related-article-type="corrected-article" id="d30e91" ext-link-type="doi" xlink:href="10.1007/s12325-013-0060-1"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Healthcare 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Erratum to: Adv Ther (2013) 30(10):870&#x02013;884 DOI 10.1007/s12325-013-0060-1</title><p>The authors of the above-mentioned paper noticed an error subsequent to publication. In the Abstract, patients with disease recurrence during or within 12&#x000a0;months of completion of adjuvant therapy are grouped with other patient subgroups as being &#x0201c;prospectively defined&#x0201d;. This subgroup was not included within the prospectively defined patient subgroups for the BOLERO-2 trial. Of note, within the article (i.e., in the Results section and in Fig.&#x000a0;2), this subgroup is described using the correct terminology. All subgroups shown in Fig.&#x000a0;2 were prospectively defined with the exception of prior chemotherapy for metastatic disease (no/yes) and last therapy setting (adjuvant/metastatic).</p><p><bold><italic>The incorrect sentence in the abstract is:</italic></bold> Final study results with median 18-month follow-up show that median PFS remained significantly longer with everolimus plus exemestane versus placebo plus exemestane [investigator review: 7.8 versus 3.2&#x000a0;months, respectively; hazard ratio&#x000a0;=&#x000a0;0.45 (95% confidence interval 0.38&#x02013;0.54); log-rank <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001; central review: 11.0 versus 4.1&#x000a0;months, respectively; hazard ratio&#x000a0;=&#x000a0;0.38 (95% confidence interval 0.31&#x02013;0.48); log-rank <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001] in the overall population and in all prospectively defined subgroups, including patients with visceral metastases, patients with recurrence during or within 12&#x000a0;months of completion of adjuvant therapy, and irrespective of age.</p><p><bold><italic>The correct sentence should read:</italic></bold> Final study results with median 18-month follow-up show that median PFS remained significantly longer with everolimus plus exemestane versus placebo plus exemestane [investigator review: 7.8 versus 3.2&#x000a0;months, respectively; hazard ratio&#x000a0;=&#x000a0;0.45 (95% confidence interval 0.38&#x02013;0.54); log-rank <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001; central review: 11.0 versus 4.1&#x000a0;months, respectively; hazard ratio&#x000a0;=&#x000a0;0.38 (95% confidence interval 0.31&#x02013;0.48); log-rank <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001] in the overall population and in all prospectively defined subgroups, including patients with visceral metastases, and irrespective of age.</p><p>The authors regret this imprecision, and thank Springer Healthcare for publishing the correction.
</p></sec></body><back><fn-group><fn><p>The online version of the original article can be found under doi:10.1007/s12325-013-0060-1.</p></fn></fn-group></back></article>